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COST-EFFECTIVENESS OF TWO REGIMENS OF TOTAL INTRAVENOUS ANESTHESIA USING INFUSION PUMP IN MEXICO
Carlos FDJ, Guzmán JA, Camacho A RAC Salud Consultores, S.A. DE C.V, Ciudad de México, Distrito Federal, Mexico OBJECTIVES: To estimate the cost-effectiveness of remifentanil/propofol versus fentanyl/propofol as regimen of total intravenous anesthesia using infusion pump in Mexican Health Sector. METHODS: An expert panel with anesthesiologists was established to identify the medical and non-medical health resources used to perform a general anesthesia in patients with 65 kg, ASA I (American Society of Anesthesiologists) for a range in the anesthetic time from 60 to 180 minutes and the effectiveness accomplished with the regimens. The information gathered from the expert panel was completed with a literature review. Official unitary costs for the Mexican Institute of Social Security (IMSS) and Hospitals from The Ministry of Health were used. The expected cost per patient included the costs of drugs, postanesthetic care unit, labor costs and costs associated with adverse events. Costs were expressed in Mexican Pesos and then converted to US dollars (rate exchange 11 Mexican pesos = 1USD). RESULTS: For the remifentanil/propofol regimen the induction doses were 1 mcg/kg remifentanil and 2 mg/kg propofol; the maintenance doses were 0.5 mcg/kg/min remifentanil and 85 mcg/kg/min. For the fentanyl/propofol group the induction doses were 3 mcg/kg fentanyl and 2 mg/kg propofol; the maintenance doses were 3 mcg/kg/hour fentanyl and 120 mcg/kg/min. For the median of anesthetic time, 120 minutes, the costs per anesthesia were $1421 (129 USD) and $1644 (149 USD) for the remifentanil/propofol and fentanyl/propofol regimen, respectively. The average extubation time was 7 minutes for the regimen with remifentanil, and 15 minutes with fentanyl. Using a visual analogue scale, where 0 represents the worst value and 10 the best, the remifentanil/propofol regimen was graded 9.6 and the fentanyl/propofol 8.6. CONCLUSIONS: Regimens with remifentanil/propofol dominates fentanyl/propofol techniques, since they provide a highly effective and secure anesthesia and also represents a significant saving in total resources used (mainly in use of propofol and post-anesthetic care unit) offsetting its higher acquisition costs. (HOSP1 and HOSP2) . The bootstrap resampling method (5000 samples) was applied to have more reliable results. RESULTS: Data of 174 patients (mean age 68.3, 38-93 years, 49.4% men) was collected: 82.8% underwent surgery for malignant cancer, 2.3% for benign cancer, 14.9% for other reasons. Antibiotic therapy was applied by adopting two different guidelines: in HOSP1 patients were treated with 5-nitroimidazole and ceftazidime or cefotassime. If infections occurred, cephalosporins, fluoroquinolones, quinolones, carbapenems, penicillines were used, according to the type of infections. Patients from HOSP2 were preventively treated with: cefotetan or cefoxitine, or 5-nitroimidazole + gentamicine or piperacilline + 5-nitroimidazole. The infected patients were treated with carbapenems, penicillines, cephalosporins, triazoles, amynoglicosides, and fluoroquinolones. Thirty-eight patients (22%) were infected, with similar frequencies in the two hospitals. Therapy cost on average €140.59 (€0.0-816.13), with significant difference between non infected and infected patients (97.24 vs. €293.99, p < 0.0001). The average cost was higher in HOSP1 (€182.45 vs. €102.40, p < 0.001) while the median post-surgical
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